We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.51%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.25B
AUM Growth
-$409M
Cap. Flow
-$35.9M
Cap. Flow %
-2.87%
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.5M
2
RGNX icon
Regenxbio
RGNX
+$19.9M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$15.6M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$14.2M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$12.7M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19M
2
AGN
Allergan plc
AGN
+$18M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$17.5M
4
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$17M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Consumer Discretionary 0.07%
3 Financials 0.04%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
76
Evolent Health
EVH
$372M
$2.19M 0.18%
137,289
-15,511
-10% -$303K
ABEOW
77
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$2.17M 0.17%
1,259,636
+9,636
+0.8% +$18.9K
CSBR icon
78
Champions Oncology
CSBR
$77.4M
$1.99M 0.16%
+372,597
New +$2.43M
BAX icon
79
Baxter International
BAX
$12.8B
$1.97M 0.16%
+60,000
New +$2.27M
CRBP icon
80
Corbus Pharmaceuticals
CRBP
$165M
$1.96M 0.16%
41,667
+12,667
+44% +$843K
INDP icon
81
Indaptus Therapeutics
INDP
$256M
$1.96M 0.16%
+156
New +$2.05M
NVTA
82
DELISTED
Invitae Corporation
NVTA
$1.82M 0.15%
251,666
-47,917
-16% -$504K
XENE icon
83
Xenon Pharmaceuticals
XENE
$6.1B
$1.7M 0.14%
205,800
-19,200
-9% -$191K
DSCI
84
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.7M 0.14%
360,584
+11,800
+3% +$76.2K
RPRX
85
DELISTED
Repros Therapeutics Inc.
RPRX
$1.64M 0.13%
+220,000
New +$1.68M
ALPN
86
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.62M 0.13%
+31,250
New +$2.05M
AVGR
87
DELISTED
Avinger, Inc. Common Stock
AVGR
$1.43M 0.11%
1
– –
GNVC
88
DELISTED
GenVec, Inc.
GNVC
$1.42M 0.11%
61,584
– –
BCRX icon
89
BioCryst Pharmaceuticals
BCRX
$2.43B
$1.41M 0.11%
123,745
-346,255
-74% -$4.62M
UUP icon
90
Invesco DB US Dollar Index Bullish Fund
UUP
$424M
$1.38M 0.11%
55,000
-35,000
-39% -$881K
CASC
91
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.38M 0.11%
591,150
+33,334
+6% +$683K
SCYX icon
92
SCYNEXIS
SCYX
$37.4M
$1.27M 0.1%
2,188
– –
SGYP
93
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.2M 0.1%
+226,000
New +$1.75M
XIV
94
DELISTED
VelocityShares Daily Inverse VIX Short Term ETN
XIV
$1.13M 0.09%
46,500
+42,500
+1,063% +$1.58M
VCEL icon
95
Vericel Corp
VCEL
$2.38B
$952K 0.08%
351,162
-177,535
-34% -$583K
BCLI
96
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$916K 0.07%
26,667
– –
IRWD icon
97
Ironwood Pharmaceuticals
IRWD
$586M
$899K 0.07%
102,957
-486,401
-83% -$4.54M
SAGE
98
DELISTED
Sage Therapeutics
SAGE
$847K 0.07%
20,000
– –
NGNE icon
99
Neurogene
NGNE
$665M
$839K 0.07%
2,980
-3,520
-54% -$811K
CGNT
100
DELISTED
Cogentix Medical, Inc.
CGNT
$835K 0.07%
673,257
– –
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q3 2015 filing shows 40 new, 31 increased, 43 reduced and 54 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M. The largest sale was ZS PHARMA INC COMS TK (DE), an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
  • Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
  • Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
  • Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
  • Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.